Andrew Staron MD
Assistant Professor, Hematology & Medical Oncology
820 Harrison Ave | (617) 638-7011
Hematology & Medical Oncology
Andrew Staron, MD is an Assistant Professor of Medicine in Hematology & Medical Oncology at the Chobanian and Avedisian School of Medicine. He was appointed to this position after completing his residency (2015–2018) and fellowship (2019–2022) at Boston Medical Center. In his third year of fellowship, Dr. Staron was selected for the role of chief fellow. Additionally, he completed a year-long clinical and research fellowship in amyloidosis (2018–2019) at the Boston University Amyloidosis Center, under the mentorship of the director, Dr. Sanchorawala.
As a practicing hematologist at Boston Medical Center, Dr. Staron has a deep commitment to serving patients and families who are affected by various hematologic diseases and who come from diverse backgrounds, drawing upon his own upbringing in an immigrant family. His main research interest is in AL amyloidosis—a rare plasma cell disorder that leads to the accumulation of abnormal immunoglobulin light chain proteins in organs. He has been the lead author on several publications in peer-reviewed journals and given presentations related to AL amyloidosis at national and international meetings. Dr. Staron helps to oversee the clinical database at the Boston University Amyloidosis Center and is directly involved in research projects utilizing this resource. He has conducted natural history studies that described important trends in disease outcomes and explored the role of minimal residual disease assessment in AL amyloidosis. Dr. Staron is also a member of the International Society of Amyloidosis and a peer-reviewer for several journals.
Medicine, MD, New York Medical College, 2015
Biology, BS, Cornell University, 2011
Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A, Kaku M, Lau KHV, Berk JL, Sloan JM, Sanchorawala V. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. Am J Hematol. 2022 Sep; 97(9):1189-1199. PMID: 35731907.Published on 7/4/2022
Staron A, Zheng L, Doros G, Sanchorawala V. Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans. Blood Cancer J. 2022 07 04; 12(7):100. PMID: 35787622.Published on 5/2/2022
Staron A, Verma K, Sanchorawala V. Prevalence of plasma cell and lymphoproliferative disorders among blood relatives of patients with light chain amyloidosis. Br J Haematol. 2022 Sep; 198(5):861-865. PMID: 35499208.Published on 8/4/2021
Staron A, Zheng L, Doros G, Connors LH, Mendelson LM, Joshi T, Sanchorawala V. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021 08 04; 11(8):139. PMID: 34349108.Published on 11/10/2020
Staron A, Connors LH, Zheng L, Doros G, Sanchorawala V. Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer J. 2020 11 10; 10(11):118. PMID: 33173025.Published on 10/7/2020
Hughes DM, Staron A, Sanchorawala V. A pharmacist's review of the treatment of systemic light chain amyloidosis. J Oncol Pharm Pract. 2021 Jan; 27(1):187-198. PMID: 33028132.Published on 3/10/2020
Staron A, Burks EJ, Lee JC, Sarosiek S, Sloan JM, Sanchorawala V. Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. Blood Adv. 2020 03 10; 4(5):880-884. PMID: 32130406.Published on 11/26/2019
Staron A, Kataria Y, Murray DL, Sloan JM, Sanchorawala V. Systemic AL amyloidosis with an undetectable plasma cell dyscrasia: A zebra without stripes. Am J Hematol. 2020 02; 95(2):E45-E48. PMID: 31736101.Published on 7/15/2019
Staron A, Connors LH, Ruberg FL, Mendelson LM, Sanchorawala V. A new era of amyloidosis: the trends at a major US referral centre. Amyloid. 2019 Dec; 26(4):192-196. PMID: 31306033.Published on 7/8/2019
Qualls DA, Lewis GD, Sanchorawala V, Staron A. Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature. Am J Transplant. 2019 11; 19(11):3185-3190. PMID: 31207062.